Institution Directory

Clinical trials at Dana-Farber Cancer Institute

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:50 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1324

Shown on this page

Current sort

Live official records

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Seattle, Washington

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 8
States / cities: Palo Alto, California • Sarasota, Florida • Boston, Massachusetts + 4 more

Conditions: Advanced Breast Cancer
Interventions: MEN2312, Elacestrant; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 37
States / cities: Springdale, Arkansas • Duarte, California • La Jolla, California + 30 more

Conditions: Neoplasms, Child, Adolescent
Interventions: Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, Temozolomide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 1 Year to 39 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Acute Myeloid Leukemia
Interventions: Tagraxofusp, Venetoclax, Azacitidine; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Los Angeles, California • Stanford, California • Miami, Florida + 17 more

Conditions: Small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 30
States / cities: Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more

Conditions: Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy
Interventions: Leukemia Profiling; Genetic
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 30 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 11 more

Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions: Datopotamab Deruxtecan; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions: Cessation of anti-HER2 treatment; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 13
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more

Conditions: Multiple Myeloma
Interventions: Cevostamab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more

Conditions: Gastric Cancer
Interventions: Short course radiation therapy, Standard of care neoadjuvant chemotherapy; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more

About this Dana-Farber Cancer Institute institution page

What this page lists: ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Dana-Farber Cancer Institute

Filter and sort this campus

Live official records

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer

About this Dana-Farber Cancer Institute institution page